Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Optamol - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Optamol

Approved

STANDARD

Optamol

Amanta Healthcare Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: ca5f85b0be25cb03
Company: Amanta Healthcare Ltd.
Type: Standard

Approval Details

Approval Id: ca5f85b0be25cb03
Drug Approval Philippines Name: Optamol
Product Name: Optamol
Registration Number: DR-XY36653
Brand Name: Optamol
Generic Name: Timolol (As Maleate)
Dosage Form: Ophthalmic Solution (Eye Drops)
Dosage Strength: 2.5 mg/Ml (0.25%w/v)
Manufacturer: Amanta Healthcare Ltd.
Importer: Endure Medical, Inc.
Distributor: Endure Medical, Inc.
Issuance Date: 28 September 2024
Expiry Date: 16 September 2029
Pharmacologic Category: Antiglaucoma / Beta-Adrenergic Blocking Agent
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

ca5f85b0be25cb03

Type

Standard

Back to Philippines FDA Approvals